REFERENCES
1. Fischer J, Walker LC, Robinson BA, Frizelle FA, Church JM, Eglinton TW. Clinical implications of the genetics of sporadic colorectal cancer. ANZ J Surg. 2019;89:1224-9.
2. Alves Martins BA, de Bulhões GF, Cavalcanti IN, Martins MM, de Oliveira PG, Martins AMA. Biomarkers in colorectal cancer: the role of translational proteomics research. Front Oncol. 2019;9:1284.
3. Cianci N, Cianci G, East JE. Colorectal cancer: prevention and early diagnosis. Medicine (Baltimore). 2024;52:251-7.
4. Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol. 2019;16:690-704.
5. Liang JQ, Li T, Nakatsu G, et al. A novel faecal Lachnoclostridium marker for the non-invasive diagnosis of colorectal adenoma and cancer. Gut. 2020;69:1248-57.
6. Shaukat A, Levin TR. Current and future colorectal cancer screening strategies. Nat Rev Gastroenterol Hepatol. 2022;19:521-31.
7. Ladabaum U, Dominitz JA, Kahi C, Schoen RE. Strategies for colorectal cancer screening. Gastroenterology. 2020;158:418-32.
8. Chen H, Li N, Ren J, et al. ; group of Cancer Screening Program in Urban China (CanSPUC). Participation and yield of a population-based colorectal cancer screening programme in China. Gut. 2019;68:1450-7.
9. Kaminski MF, Robertson DJ, Senore C, Rex DK. Optimizing the quality of colorectal cancer screening worldwide. Gastroenterology. 2020;158:404-17.
10. Senore C, Basu P, Anttila A, et al. Performance of colorectal cancer screening in the European Union Member States: data from the second European screening report. Gut. 2019;68:1232-44.
11. Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 2019;68:1014-23.
12. Jiao N, Baker SS, Chapa-Rodriguez A, et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut. 2018;67:1881-91.
13. Chen D, Wu J, Jin D, Wang B, Cao H. Fecal microbiota transplantation in cancer management: current status and perspectives. Int J Cancer. 2019;145:2021-31.
14. Chen G, Ren Q, Zhong Z, et al. Exploring the gut microbiome’s role in colorectal cancer: diagnostic and prognostic implications. Front Immunol. 2024;15:1431747.
15. Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021;19:55-71.
16. Ternes D, Tsenkova M, Pozdeev VI, et al. The gut microbial metabolite formate exacerbates colorectal cancer progression. Nat Metab. 2022;4:458-75.
17. Villéger R, Lopès A, Veziant J, et al. Microbial markers in colorectal cancer detection and/or prognosis. World J Gastroenterol. 2018;24:2327-47.
18. Kim SH, Lim YJ. The role of microbiome in colorectal carcinogenesis and its clinical potential as a target for cancer treatment. Intest Res. 2022;20:31-42.
19. McQuade JL, Daniel CR, Helmink BA, Wargo JA. Modulating the microbiome to improve therapeutic response in cancer. Lancet Oncol. 2019;20:e77-91.
20. Jin S, Zhong W, Li B, Wang K, Lai D. Multidimensional analysis of the impact of Gemmatimonas, Rhodothermus, and Sutterella on drug and treatment response in colorectal cancer. Front Cell Infect Microbiol. 2024;14:1457461.
21. Quince C, Walker AW, Simpson JT, Loman NJ, Segata N. Shotgun metagenomics, from sampling to analysis. Nat Biotechnol. 2017;35:833-44.
22. Kubinski R, Djamen-Kepaou JY, Zhanabaev T, et al. Benchmark of data processing methods and machine learning models for gut microbiome-based diagnosis of inflammatory bowel disease. Front Genet. 2022;13:784397.
23. Lee S, Lee I. Comprehensive assessment of machine learning methods for diagnosing gastrointestinal diseases through whole metagenome sequencing data. Gut Microbes. 2024;16:2375679.
24. Costea PI, Zeller G, Sunagawa S, et al. Towards standards for human fecal sample processing in metagenomic studies. Nat Biotechnol. 2017;35:1069-76.
25. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165:710-8.
26. Nearing JT, Douglas GM, Hayes MG, et al. Microbiome differential abundance methods produce different results across 38 datasets. Nat Commun. 2022;13:342.
27. Weiss S, Xu ZZ, Peddada S, et al. Normalization and microbial differential abundance strategies depend upon data characteristics. Microbiome. 2017;5:27.
28. Ling W, Zhao N, Plantinga AM, et al. Powerful and robust non-parametric association testing for microbiome data via a zero-inflated quantile approach (ZINQ). Microbiome. 2021;9:181.
29. Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334:105-8.
30. Vujkovic-Cvijin I, Sklar J, Jiang L, Natarajan L, Knight R, Belkaid Y. Host variables confound gut microbiota studies of human disease. Nature. 2020;587:448-54.
31. Forslund SK, Chakaroun R, Zimmermann-Kogadeeva M, et al. ; MetaCardis Consortium*. Combinatorial, additive and dose-dependent drug-microbiome associations. Nature. 2021;600:500-5.
32. He Y, Wu W, Zheng HM, et al. Regional variation limits applications of healthy gut microbiome reference ranges and disease models. Nat Med. 2018;24:1532-5.
33. Li M, Liu J, Zhu J, et al. Performance of gut microbiome as an independent diagnostic tool for 20 diseases: cross-cohort validation of machine-learning classifiers. Gut Microbes. 2023;15:2205386.
34. Li P, Li M, Chen WH. Best practices for developing microbiome-based disease diagnostic classifiers through machine learning. Gut Microbes. 2025;17:2489074.
35. Leinonen R, Akhtar R, Birney E, et al. The European nucleotide archive. Nucleic Acids Res. 2011;39:D28-31.
36. Sun Y, Wu S, Wu Z, et al. Instance-based transfer learning enables cross-cohort early detection of colorectal cancer. bioRxiv 2025; bioRxiv:2025.2002.2022.639690. Available from: https://doi.org/10.1101/2025.02.22.639690 [accessed 27 November 2025].
37. Chen Y, Li J, Zhang Y, et al. Parallel-Meta Suite: interactive and rapid microbiome data analysis on multiple platforms. Imeta. 2022;1:e1.
38. Wirbel J, Zych K, Essex M, et al. Microbiome meta-analysis and cross-disease comparison enabled by the SIAMCAT machine learning toolbox. Genome Biol. 2021;22:93.
39. Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.
40. Ma S, Shungin D, Mallick H, et al. Population structure discovery in meta-analyzed microbial communities and inflammatory bowel disease using MMUPHin. Genome Biol. 2022;23:208.
41. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012;28:882-3.
42. Kaul A, Mandal S, Davidov O, Peddada SD. Analysis of microbiome data in the presence of excess zeros. Front Microbiol. 2017;8:2114.
43. Paulson JN, Stine OC, Bravo HC, Pop M. Differential abundance analysis for microbial marker-gene surveys. Nat Methods. 2013;10:1200-2.
44. Mallick H, Rahnavard A, McIver LJ, et al. Multivariable association discovery in population-scale meta-omics studies. PLoS Comput Biol. 2021;17:e1009442.
45. Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12:R60.
46. Frazier PI. A tutorial on Bayesian optimization. arXiv 2018; arXiv:1807.02811. Available from: https://doi.org/10.48550/arXiv.1807.02811 [accessed 27 November 2025].
47. R Core Team. R: A language and environment for statistical computing. MSOR connections Available from: https://api.semanticscholar.org/CorpusID:215755663. [accessed 27 November 2025].
48. Forslund K, Hildebrand F, Nielsen T, et al. ; MetaHIT consortium. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015;528:262-6.
49. Maier L, Pruteanu M, Kuhn M, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018;555:623-8.
50. Blanco-Míguez A, Beghini F, Cumbo F, et al. Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4. Nat Biotechnol. 2023;41:1633-44.
51. Beghini F, McIver LJ, Blanco-Míguez A, et al. Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. Elife. 2021;10.
52. McDonald D, Jiang Y, Balaban M, et al. Greengenes2 unifies microbial data in a single reference tree. Nat Biotechnol. 2024;42:715-8.
53. Gihawi A, Ge Y, Lu J, et al. Major data analysis errors invalidate cancer microbiome findings. mBio. 2023;14:e0160723.
54. Li H. Microbiome, metagenomics, and high-dimensional compositional data analysis. Annu Rev Stat Appl. 2015;2:73-94.
55. Gloor GB, Macklaim JM, Pawlowsky-Glahn V, Egozcue JJ. Microbiome datasets are compositional: and this is not optional. Front Microbiol. 2017;8:2224.
56. Dai D, Zhu J, Sun C, et al. GMrepo v2: a curated human gut microbiome database with special focus on disease markers and cross-dataset comparison. Nucleic Acids Res. 2022;50:D777-84.
57. Zeller G, Tap J, Voigt AY, et al. Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol Syst Biol. 2014;10:766.
58. Feng Q, Liang S, Jia H, et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat Commun. 2015;6:6528.
59. Elahi Z, Shariati A, Bostanghadiri N, et al. Association of lactobacillus, firmicutes, bifidobacterium, clostridium, and enterococcus with colorectal cancer in Iranian patients. Heliyon. 2023;9:e22602.
60. Zhou P, Dai Z, Xie Y, et al. Differences in tissue-associated bacteria between metastatic and non-metastatic colorectal cancer. Front Microbiol. 2023;14:1133607.
61. Zhernakova A, Kurilshikov A, Bonder MJ, et al. LifeLines cohort study. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science. 2016;352:565-9.
